Free Trial
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel
NASDAQ:NYXH

Nyxoah Q4 2025 Earnings Report

Nyxoah logo
$1.59 +0.01 (+0.63%)
Closing price 06/17/2026 04:00 PM Eastern
Extended Trading
$1.44 -0.15 (-9.69%)
As of 06/17/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Nyxoah EPS Results

Actual EPS
-$0.69
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Nyxoah Revenue Results

Actual Revenue
$6.62 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Nyxoah Announcement Details

Quarter
Q4 2025
Date
2/14/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Nyxoah's Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled at 3:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Nyxoah Earnings Headlines

Publication relating to transparency notifications
June 17 at 4:30 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313828/0/en/publication-relating-to-transparency-notifications.html
Nyxoah Receives $15 Million from the European Investment Bank
June 17 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/17/3313803/0/en/nyxoah-receives-15-million-from-the-european-investment-bank.html
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
 |  Profits Run (Ad)
Nyxoah’s Genio® Wins Prix Galien UK 2026 Award for Best Medical Technology
June 16 at 1:34 PM  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/nyxoah-genio-wins-prix-galien-200500422.html
Information on the total number of voting rights and shares
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3310136/0/en/information-on-the-total-number-of-voting-rights-and-shares.html
$110 Million in Aggregate Financings to Accelerate Genio's U.S. Commercial Launch
June 10, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/10/3310114/0/en/110-million-in-aggregate-financings-to-accelerate-genio-s-u-s-commercial-launch.html
See More Nyxoah Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nyxoah? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nyxoah and other key companies, straight to your email.

About Nyxoah

Nyxoah (NASDAQ:NYXH), headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient. Prior to bedtime, users apply the activation patch, which wirelessly powers the implant and delivers timed electrical pulses to the tongue muscles. Following a CE mark in 2019, Nyxoah initiated commercial launches across Europe and select international markets. The company is actively pursuing additional regulatory clearances, including a premarket application with the U.S. Food and Drug Administration, and is conducting ongoing clinical studies to expand the system’s indications and validate long-term safety and efficacy.

Building on its flagship product, Nyxoah continues to invest in research and development aimed at next-generation neuromodulation platforms for various sleep-related disorders. The company maintains a global footprint with commercial operations in Europe and a subsidiary in the United States, and collaborates with leading sleep centers to drive physician adoption and patient access. Nyxoah’s management team combines expertise in medical devices, sleep medicine, and implantable technologies to advance its mission of improving outcomes for patients suffering from obstructive sleep apnea.

View Nyxoah Profile
Earnings Tools